NCT05667246View on ClinicalTrials.gov

Clinical Effect of Caffeine Consumption in Patients Taking Oral Terbinafine

NAEnrolling by invitationINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

July 25, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Terbinafine Adverse Reaction
Interventions
OTHER

Caffeinated Coffee

"Subjects would be randomized to a group Caffeinated and subjects will be 95 mg of caffeine in caffeinated coffee."

OTHER

Decaffeinated Coffee

"Subjects would be randomized to a group Decaffeinated and subjects will be no caffeine in decaffeinated coffee."

Trial Locations (1)

10021

Weill Cornell Medicine, New York

All Listed Sponsors
lead

Weill Medical College of Cornell University

OTHER

NCT05667246 - Clinical Effect of Caffeine Consumption in Patients Taking Oral Terbinafine | Biotech Hunter | Biotech Hunter